Loading...

APC/Cyanine7 Streptavidin

Pricing & Availability
Regulatory Status
RUO
Ave. Rating
Submit a Review
Product Citations
publications
APCCyanine7_Streptavidin_Antibody_042123
Human peripheral blood lymphocytes were stained with APC/Cyanine7 streptavidin alone (open histogram) or Biotin anti-human CD3 (clone UCHT1) followed by (APC/Cyanine7) Streptavidin (filled histogram).
  • APCCyanine7_Streptavidin_Antibody_042123
    Human peripheral blood lymphocytes were stained with APC/Cyanine7 streptavidin alone (open histogram) or Biotin anti-human CD3 (clone UCHT1) followed by (APC/Cyanine7) Streptavidin (filled histogram).
See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
405208 100 µg 165€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-APC/Cyanine7 is useful for detecting biotinylated antibodies. The excitation of APC/Cyanine7 by 600-635 nm laser light induces a fluorescence emission maximum of 780 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The Streptavidin APC/Cyanine7 solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

Each lot of this Streptavidin APC/Cyanine7 is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the APC/Cyanine7 conjugation. For immunofluorescent staining, the recommended use of this reagent is =0.06 µg per 106 cells in 100 µl staining volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Streptavidin-Allophycocyanin/Cyanine7 (APC/Cyanine7) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-APC/Cyanine7 is 350 kD and Streptavidin alone is 52 kD.

Additional Product Notes

BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)
  1. Maresz K, et al. 2005. J. Neurochemistry 95:437.
  2. Ponomarev ED, et al. 2006. J. Immunol. 176:1402.PubMed.
  3. Ponomarev ED, et al. 2007. J. Immunol. 178:39.
  4. Mann MK, et al. 2007. J. Immunol. 178:3447.PubMed
  5. Ponomarev ED,et al.2005.J. Immunol Methods.300:32. PubMed
  6. Cao YA, et al. 2008. Blood PubMed
  7. Garidou L, et al. 2009. J. Virol. PubMed
  8. Dolgachev V, et al. 2009. J. Immunol. 183:5705. PubMed
  9. Sountoulidis A, et al. 2012. PLoS One. 7:e41460. PubMed.
  10. Izumi T, et al. 2013. Cytotherapy. 15:481. PubMed
  11. Hamanaka S, et al. 2013. Biochem Biophys Res Commun. 435:586. PubMed
  12. Prince J, et al. 2013. J. Immunol. 191:4709. PubMed
  13. Phanse Y, et al. 2013. Acta Biomater. 9:8902. PubMed
  14. Orre M, et al. 2014. Neurbiol Aging. 35:1. PubMed
  15. Barbera M, et al. 2014. Gut. 64:11. PubMed
  16. Zhang Y, et al. 2014. Infect Immun. 82:1698. PubMed
  17. Peterson BC, et al. 2014. J Leukoc Biol. 95:809. PubMed
  18. Barbera M, et al. 2015. Gut. 64:11. PubMed
  19. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
Product Citations
  1. Zhang Y, et al. 2014. Infect Immun . 82:1689. PubMed
  2. Petersen B, et al. 2014. J Leukoc Biol. 95:809. PubMed
  3. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
  4. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  5. Ponomarev E, et al. 2006. J Immunol. 176:1402. PubMed
  6. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  7. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  8. Rohde D, et al. 2022. Nat Cardiovasc Res. 1:28. PubMed
  9. Orre M, et al. 2014. Neurobiol Aging. 35:1. PubMed
  10. Gudjonsson A, et al. 2019. Front Immunol. 10:1086. PubMed
  11. Gutiérrez-Gutiérrez Ó, et al. 2021. EMBO Rep. 22:e52905. PubMed
  12. Barbera M, et al. 2015. Gut. 64:11. PubMed
  13. Bonnet C, et al. 2021. iScience. 24:103399. PubMed
  14. Prince J, et al. 2013. J Immunol. 191:4709. PubMed
  15. Phanse Y, et al. 2013. Acta Biomater. 9:8902. PubMed
  16. Seri Y, et al. 2015. Sci Rep. 5: 13041. PubMed
  17. Lin K, et al. 2016. Sci Rep. 6:31444. PubMed
  18. Wu T, et al. 2021. BMC Biotechnol. 21:42. PubMed
  19. Sánchez-Salguero E, et al. 2021. Front Immunol. 12:712130. PubMed
  20. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  21. Keller EJ, et al. 2021. Front Immunol. 616064:11. PubMed
  22. Yeo S, et al. 2016. Cancer Res . 76: 3397 - 3410. PubMed
  23. Izumi T, et al. 2013. Cytotherapy. 15:481. PubMed
  24. Kimball A, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1102. PubMed
  25. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  26. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  27. Ritter M, et al. 2020. Ann Hematol. 99:2329. PubMed
  28. Ponomarev ED, et al. 2005. J Immunol Methods. 300:32:00. PubMed
  29. Barman PK, et al. 2019. J Immunol. 202:2720. PubMed
  30. Chen Y, et al. 2015. PLoS One. 10: 0135217. PubMed
  31. Greenwald AC, et al. 2019. J Exp Med. 216:215. PubMed
  32. Zhu H, et al. 2020. J Bone Miner Res. 35:698. PubMed
  33. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  34. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  35. Lebert-Ghali C, et al. 2016. Blood. 127: 87-90. PubMed
  36. Omer OS, et al. 2020. Methods Mol Biol. 2121:199. PubMed
  37. Shimizu T, et al. 2016. J Exp Med. 213: 1479 - 1496. PubMed
  38. Gillespie A, et al. 2016. PLoS One. 12: 1005419. PubMed
  39. Chao D, et al. 2015. PLoS One. 10: 0138107. PubMed
  40. Hamanaka S, et al. 2013. Biochem Biophys Res Commun. 435:586. PubMed
  41. Dolgachev V, et al. 2009. J Immunol. 183:5705. PubMed
  42. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  43. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  44. Freter R, et al. 2021. Nat Commun. 12:3318. PubMed
  45. Mann M, et al. 2007. J Immunol . 178:3447. PubMed
  46. Giraddi R, et al. 2015. Nat Commun. 6: 8487. PubMed
  47. Cao Y, et al. 2008. Blood. 112:4494. PubMed
  48. Kulkarni N, et al. 2017. Eur J Appl Physiol.. 10.1007/s00421-017-3704-z. PubMed
  49. Keller EJ, et al. 2022. Int J Mol Sci. 23:. PubMed
  50. King R, et al. 2021. Sci Adv. 7:eabj5293. PubMed
  51. Ho JY, et al. 2021. Mol Ther Methods Clin Dev. 21:237. PubMed
  52. Sountoulidis A, et al. 2012. PLoS One. 7:e41460. PubMed
  53. Kimball AS, et al. 2020. Thromb Haemost. 120:289. PubMed
  54. Chen Z, et al. 2020. Cell Death Dis. 11:180. PubMed
  55. Mesnieres M, et al. 2021. Cell Reports. 36(8):109618. PubMed
  56. Thürmer M, et al. 2022. Nat Commun. 13:2982. PubMed
  57. Wang J, et al. 2022. Elife. 11:. PubMed
  58. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  59. Furusawa J, et al. 2016. PLoS Pathog. 12: 1005507. PubMed
  60. Sen D, et al. 2016. PLoS One. 11:e0165064. PubMed
  61. Li ZG, et al. 2020. Chin Med J (Engl). 1943:133. PubMed
  62. Garidou L, et al. 2009. J Virol. 83:8905. PubMed
  63. Schafer JB, et al. 2022. J Biol Chem. :102694. PubMed
  64. Song W, et al. 2022. Immunity. 55:290. PubMed
  65. Man N, et al. 2021. JCI Insight. 6:. PubMed

Related FAQs

There are no FAQs for this product.
Go To Top Version: 5    Revision Date: 04.21.2023

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account